Navigation Links
SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
Date:1/9/2012

SAN FRANCISCO, January 9, 2012 /PRNewswire/ --

SFJ Pharma Ltd. II (President & CEO: Robert F. DeBenedetto, "SFJ") announced today that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial in Asia of Pfizer's investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.

Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, receptors that can influence tumor growth, vascular angiogenesis and progression of cancer. It has been widely studied in a broad clinical development program, evaluating its efficacy and safety in more than 2,500 patients across several tumor types. Axitinib is currently under review by the U.S. Food and Drug Administration, the European Medicines Agency, the Japanese Ministry of Health, Labour and Welfare, and several other regulatory agencies around the world as a treatment for advanced RCC.

Under the terms of the agreement, SFJ will provide the funding and clinical development supervision to generate the clinical data necessary to submit axitinib for review by regulatory authorities for the adjuvant treatment of patients at high risk of recurrent RCC following nephrectomy. SFJ will be eligible to receive milestone payments under the agreement.

In addition, if approved, Pfizer intends to commercialize axitinib for this indication and SFJ will receive earn- out payments under the agreement. "We appreciate the opportunity to collaborate with Pfizer for one of their most promising oncology compounds," said Robert DeBenedetto. "We believe SFJ's new co-development model will benefit patients by allowing Pharma companies like Pfizer to develop even more compounds simultaneously."

"We recognize the need to look for new and innovative ways to advance our clinical programs and bring our many promising compounds to pat
'/>"/>

SOURCE SFJ Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Reata Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
2. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
3. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
4. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
5. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
10. The respective roles of the public and private sectors in pharmaceutical innovation
11. PDL BioPharma Completes Regular Quarterly Dividend Payment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014. Applied DNA Sciences, ... provides DNA-based authentication and security solutions and services, has ... Life Sciences, a newly created position, with a starting ... lead APDN’s drive to build its business in pharmaceuticals ... customers, provide guidance to APDN’s R&D efforts, and apply ...
(Date:7/30/2014)... July 30, 2014  Dyadic International, Inc. ("Dyadic") ... patented and proprietary technologies are used to discover, ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... "Tom" Dubinski as Vice President and Chief Financial ... financial and information technology operations for Dyadic and ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 NCERC ... Athmanathan will present his findings on corn stover ... conference this week in Washington, D.C. , ... Energy conference is a testament to the success ... Caupert said. “Thanks to the foresight and vision ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
Breaking Biology Technology:Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... Ill. and ST. PAUL, Minn., April ... promote and distribute Abbott,s FreeStyle,Navigator Continuous ... Medical MD is the manufacturer,of the ... and the Deltec Cozmo,insulin pump., ...
... Lorus Therapeutics Inc.,(,Lorus,), a biopharmaceutical company specializing ... and technologies for the management,of cancer, today ... aimed at,expanding the therapeutic application of its ... superficial bladder cancer., The new development ...
... to Tap Alternative Energy Business in China, ... Ltd ("JIC" or "the Company") to be renamed ... a wholly-owned subsidiary of HKC,(Holdings) Limited ("HKC (HOLDINGS) ... in three alternative energy projects at the Lunaobao,Wind ...
Cached Biology Technology:Smiths Medical to Promote and Distribute Abbott's FreeStyle Navigator Continuous Glucose Monitoring System 2Smiths Medical to Promote and Distribute Abbott's FreeStyle Navigator Continuous Glucose Monitoring System 3Smiths Medical to Promote and Distribute Abbott's FreeStyle Navigator Continuous Glucose Monitoring System 4Lorus initiates development program exploring novel route of administration for LOR-2040 2Lorus initiates development program exploring novel route of administration for LOR-2040 3Lorus initiates development program exploring novel route of administration for LOR-2040 4JIC Invests in Three New Alternative Energy Projects 2JIC Invests in Three New Alternative Energy Projects 3JIC Invests in Three New Alternative Energy Projects 4JIC Invests in Three New Alternative Energy Projects 5
(Date:7/30/2014)... colors, nature had already perfected the process think ... example. Now scientists are tapping into those secrets to ... plastics. Their paper on using structure or the ... to produce color appears in the ACS journal ... and colleagues point out that currently, plastic manufacturers add ...
(Date:7/30/2014)... today published new research from Bjorn Brembs, professor of ... Germany, with a proof-of-concept figure allowing readers and reviewers ... This represents an important leap forward for scientific ... the quality of a scholarly output. , Figure 3 ... data and their code to F1000Research , and ...
(Date:7/30/2014)... Wallerian degeneration is a subject of major interest ... differentially regulated during the distinct stages of Wallerian ... differentiation and dedifferentiation. Although gene expression responses in ... peripheral nerve injury are known, differences in gene ... unclear. Dr. Dengbing Yao and co-workers from Nantong ...
Breaking Biology News(10 mins):F1000Research brings static research figures to life 2
... techniques, advanced computer simulation and next generation sequencing technology, ... and the Massachusetts Institute of Technology (MIT) have resolved ... chromosomes were first observed under the light microscope by ... that appears in the online edition of Science ...
... known to repair their tissues effortlessly, but can this capacity ... the Stem Cell Program at Boston Children,s Hospital suggests that ... is active in embryonic stem cells, researchers were able to ... tissues in a mouse model. The study also ...
... Bethesda, Md. (Nov. 7, 2013)Obesity has more than doubled ... States in the past 30 years, according to the ... of childhood obesity is a major health concern since ... developing several diseases once considered reserved for adults. These ...
Cached Biology News:UMMS researchers answer century old question about 3D structure of mitotic chromosomes 2UMMS researchers answer century old question about 3D structure of mitotic chromosomes 3UMMS researchers answer century old question about 3D structure of mitotic chromosomes 4Researchers regrow hair, cartilage, bone, soft tissues 2For obese teen girls, aerobic exercise may trump resistance training in health benefits 2For obese teen girls, aerobic exercise may trump resistance training in health benefits 3
Rat Cardiac Fibroblasts (RCF) (>500,000 cells)...
... The standard of the Axima range, ... high mass accuracy, resolution, sensitivity and ... with both linear and reflectron time-of-flight ... reflectron enables the generation of seamless ...
Rat Dermal Fibroblasts (RDF) (>500,000 cells)...
... miVac Duo is suitable for use with ... organic solvents through to water and some ... centrifugal concentrator capable of removing water and ... formats including tubes, microplates, vials and round ...
Biology Products: